Celldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex announced early completion of enrollment in its pivotal Phase 3 chronic spontaneous urticaria (CSU) studies for barzolvolimab, six months ahead of guidance, with topline data expected in Q4 2026. The company capitalized on this momentum by raising $345 million in gross proceeds from a follow-on public offering closed in April 2026, extending its cash runway into 2028.
Key figures
- Revenue
- 15000
- Guidance
- Cash runway sufficient to fund planned operations through 2028
- Revenue Yoy
- -97.8%
- Deal Value Usd
- 345000000
- Shares Offered
- 11896750
- Net loss
- 78700000
- Rd expenses
- 73000000
- Cash position
- 451500000
- Patients enrolled csu
- 1939
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.